Published on December 3, 2009 at 11:10 AM
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot of the Attention-Deficit/Hyperactivity Disorder (ADHD) patch Daytrana®. Shire is taking this action because some Daytrana patches do not meet or in the future may not meet their release liner removal specification, and as a result, patients and caregivers could have difficulty removing the liners.
This action is not due to safety issues. All Daytrana patches can continue to be used unless the release liner cannot be removed or the patches are damaged while being opened. The current supply levels of Daytrana should be sufficient to ensure that patients can continue to have their Daytrana prescriptions filled at their local pharmacy.
Physicians, patients, and caregivers who have questions about Daytrana should call Shire's Daytrana customer service line at 1-800-828-2088, option 1, and pharmacists should call 1-888-871-7113.
SOURCE Shire plc
921b8ca7-5f45-4dea-ad84-bec83f64c178|0|.0
Posted in: Device / Technology News | Medical Condition News
Tags: Anxiety, Bipolar Disorder, Blood Pressure, CDC, Depression, Glaucoma, Nausea, Psychiatry, Psychosis, Vomiting, Weight Loss